Nuvation Bio, Inc. Class A (NUVB)

Nuvation Bio's stock has been impacted by several events. The FDA granted full approval to taletrectinib in June 2025. Nuvation Bio Inc. was dropped from the Russell 2000 Growth Index on June 26, 2025. The company initiated treatment for 432 new patients with IBTROZI since its launch. Philippe Sauvage was appointed as Chief Financial Officer on October 7, 2025. Truist Securities initiated coverage with a Buy rating and an $11 price target on November 24, 2025. Chief Medical Officer Liu Dongfang executed a significant sale of company stock on December 1, 2025. Nuvation Bio received a $25 million milestone payment from Nippon Kayaku in Q4 2025. UBS initiated coverage of Nuvation Bio with a Neutral rating and a $10 price target on January 7, 2026. Nuvation Bio reported positive Phase 2 results for safusidenib on January 12, 2026. The company announced an exclusive licensing agreement with Eisai Co., Ltd. for taletrectinib on January 12, 2026. Nuvation Bio reported preliminary fourth-quarter and full-year 2025 financial results and provided a 2026 outlook on January 12, 2026. H.C. Wainwright raised its price target for Nuvation Bio from $10 to $18, maintaining a Buy rating, though it later cut the price target to $17 on the same day. The stock experienced a substantial increase of 136.4% in the past 90 days. The stock fell by -24.00% in the past week, and by -21.32% in the past month.

There is no clear or reliable demand seasonality for Nuvation Bio's products and services due to insufficient data for seasonal analysis.

Nuvation Bio, Inc. is a global clinical-stage biopharmaceutical company focused on developing differentiated and novel therapeutic candidates to address unmet needs in oncology. Taletrectinib, an oral ROS1 inhibitor, received full FDA approval in June 2025 and is approved in China and Japan. Safusidenib, a brain-penetrant IDH1 inhibitor, is in Phase 2 clinical trials for gliomas. NUV-1511 is a drug-drug conjugate designed for targeted cancer therapy. NUV-868 is a BD2-selective BET inhibitor.

Nuvation Bio is dual-headquartered in New York and San Francisco, with offices in Boston and Shanghai. The company has an exclusive licensing agreement with Eisai Co., Ltd. for taletrectinib in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, and India. Nuvation Bio retains full U.S. commercial rights and leads global development for taletrectinib.

Nuvation Bio's brand reputation has been positively influenced by advancements in oncology drug development and commercialization efforts. The FDA approval of taletrectinib and positive Phase 2 clinical results for safusidenib contribute to a strong scientific and medical reputation. The company's focus on addressing significant unmet needs in cancer treatment and developing novel therapies underpins its positive reputation.

Nuvation Bio's ownership is a mix of institutional, insider, and retail investors. Institutional shareholders hold approximately 61.67% of the company's stock, while insiders own about 29.93%. Major institutional owners include Fmr LLC, Decheng Capital LLC, BlackRock, Inc., Vanguard Group Inc, Laurion Capital Management LP, Omega Fund Management, LLC, State Street Corp, Dimensional Fund Advisors LP, Aisling Capital Management LP, and Two Sigma Investments LP. Key individual owners and insiders include David Hung, Oleg Nodelman, Xiangmin Cui, Kim D Blickenstaff, Robert Mashal, Dongfang Liu, and Gary Hattersley.